NCT02219711: Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

NCT02219711
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Symptomatic or uncontrolled brain metastases
https://ClinicalTrials.gov/show/NCT02219711

Comments are closed.

Up ↑